Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2014

Open Access 01-12-2014 | Research article

Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate

Authors: Charlotte Kageneck, Barbara E Nixdorf-Bergweiler, Karl Messlinger, Michael JM Fischer

Published in: The Journal of Headache and Pain | Issue 1/2014

Login to get access

Abstract

Background

CGRP is contained in a substantial proportion of unmyelinated trigeminal neurons innervating intracranial tissues. Previously, we have described a hemisected rodent scull preparation and later the intact trigeminal ganglion to measure stimulated CGRP release from trigeminal afferents.

Methods

Here, we establish a preparation for examining CGRP release from central trigeminal terminals using single fresh slices of the mouse medullary brainstem.

Results

Basal and stimulated amount of CGRP substantially exceeded the detection level. Experiments were designed as matched pairs of at least six brainstem slices per animal. Stimulation with high potassium induced calcium-dependent and reversible CGRP release. Capsaicin stimulation of TRPV1 provoked concentration-dependent CGRP release. The anti-migraine drug naratriptan did not inhibit capsaicin-induced CGRP release from peripheral terminals but inhibited the release from brainstem slices. The glutamate antagonist kynurenate showed a similar pattern of site-specific inhibition of CGRP release.

Conclusions

As observed earlier for other drugs used in the treatment of migraine this indicates that the central terminals in the spinal trigeminal nucleus may be the main site of action. The preparation allows evaluating the trigeminal brainstem as a pharmacological site of action.
Appendix
Available only for authorised users
Literature
1.
Brain SD, Cox HM: Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 2006, 147(Suppl 1):S202-S211.PubMedCentralPubMed
2.
Goadsby PJ, Edvinsson L, Ekman R: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988, 23: 193–196. 10.1002/ana.410230214CrossRefPubMed
3.
Hoffmann J, Wecker S, Neeb L, Dirnagl U, Reuter U: Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF. Cephalalgia 2012, 32: 659–667. 10.1177/0333102412447701CrossRefPubMed
4.
Levine JD, Fields HL, Basbaum AI: Peptides and the primary afferent nociceptor. J Neurosci 1993, 13: 2273–2286.PubMed
5.
Franco-Cereceda A, Saria A, Lundberg JM: Ischaemia and changes in contractility induce release of calcitonin gene-related peptide but not neuropeptide Y from the isolated perfused guinea-pig heart. Acta Physiol Scand 1987, 131: 319–320. 10.1111/j.1748-1716.1987.tb08244.xCrossRefPubMed
6.
Perney TM, Hirning LD, Leeman SE, Miller RJ: Multiple calcium channels mediate neurotransmitter release from peripheral neurons. Proc Natl Acad Sci USA 1986, 83: 6656–6659. 10.1073/pnas.83.17.6656PubMedCentralCrossRefPubMed
7.
Saria A, Gamse R, Petermann J, Fischer JA, Theodorsson-Norheim E, Lundberg JM: Simultaneous release of several tachykinins and calcitonin gene-related peptide from rat spinal cord slices. Neurosci Lett 1986, 63: 310–314. 10.1016/0304-3940(86)90376-9CrossRefPubMed
8.
Loyd DR, Sun XX, Locke EE, Salas MM, Hargreaves KM: Sex differences in serotonin enhancement of capsaicin-evoked calcitonin gene-related peptide release from human dental pulp. Pain 2012, 153: 2061–2067. 10.1016/j.pain.2012.06.018PubMedCentralCrossRefPubMed
9.
Ebersberger A, Averbeck B, Messlinger K, Reeh PW: Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999, 89: 901–907. 10.1016/S0306-4522(98)00366-2CrossRefPubMed
10.
Eberhardt M, Hoffmann T, Sauer SK, Messlinger K, Reeh PW, Fischer MJ: Calcitonin gene-related peptide release from intact isolated dorsal root and trigeminal ganglia. Neuropeptides 2008, 42: 311–317. 10.1016/j.npep.2008.01.002CrossRefPubMed
11.
Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I: mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1 F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain 2012, 153: 830–838. 10.1016/j.pain.2012.01.005CrossRefPubMed
12.
Tringali G, Greco MC, Capuano A, Guerriero G, Curro D, Navarra P: Flupirtine inhibits calcitonin-gene related peptide release from rat brainstem in vitro. Neurosci Lett 2012, 506: 332–335. 10.1016/j.neulet.2011.11.039CrossRefPubMed
13.
Fischer MJ, Koulchitsky S, Messlinger K: The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 2005, 25: 5877–5883. 10.1523/JNEUROSCI.0869-05.2005CrossRefPubMed
14.
Levy D, Burstein R, Strassman AM: Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005, 58: 698–705. 10.1002/ana.20619CrossRefPubMed
15.
Sixt ML, Messlinger K, Fischer MJ: Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain 2009, 132: 3134–3141. 10.1093/brain/awp168CrossRefPubMed
16.
Storer RJ, Akerman S, Goadsby PJ: Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004, 142: 1171–1181. 10.1038/sj.bjp.0705807PubMedCentralCrossRefPubMed
17.
Bretag AH: Synthetic interstitial fluid for isolated mammalian tissue. Life Sci 1969, 8: 319–329.CrossRefPubMed
18.
Averbeck B, Reeh PW: Interactions of inflammatory mediators stimulating release of calcitonin gene-related peptide, substance P and prostaglandin E(2) from isolated rat skin. Neuropharmacology 2001, 40: 416–423. 10.1016/S0028-3908(00)00171-4CrossRefPubMed
19.
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM: Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982, 298: 240–244. 10.1038/298240a0CrossRefPubMed
20.
Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983, 304: 129–135. 10.1038/304129a0CrossRefPubMed
21.
Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J: Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985, 62: 131–136. 10.1016/0304-3940(85)90296-4CrossRefPubMed
22.
Ju G, Hokfelt T, Brodin E, Fahrenkrug J, Fischer JA, Frey P, Elde RP, Brown JC: Primary sensory neurons of the rat showing calcitonin gene-related peptide immunoreactivity and their relation to substance P-, somatostatin-, galanin-, vasoactive intestinal polypeptide- and cholecystokinin-immunoreactive ganglion cells. Cell Tissue Res 1987, 247: 417–431.CrossRefPubMed
23.
Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L: Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002, 22: 112–116. 10.1046/j.1468-2982.2002.00324.xCrossRefPubMed
24.
McNeill DL, Chung K, Carlton SM, Coggeshall RE: Calcitonin gene-related peptide immunostained axons provide evidence for fine primary afferent fibers in the dorsal and dorsolateral funiculi of the rat spinal cord. J Comp Neurol 1988, 272: 303–308. 10.1002/cne.902720212CrossRefPubMed
25.
Tuchscherer MM, Seybold VS: A quantitative study of the coexistence of peptides in varicosities within the superficial laminae of the dorsal horn of the rat spinal cord. J Neurosci 1989, 9: 195–205.PubMed
26.
Fischer MJ, Reeh PW, Sauer SK: Proton-induced calcitonin gene-related peptide release from rat sciatic nerve axons, in vitro, involving TRPV1. Eur J Neurosci 2003, 18: 803–810. 10.1046/j.1460-9568.2003.02811.xCrossRefPubMed
27.
Capuano A, Curro D, Navarra P, Tringali G: Cortistatin modulates calcitonin gene-related peptide release from neuronal tissues of rat. Comparison with somatostatin. Peptides 2011, 32: 138–143. 10.1016/j.peptides.2010.09.018CrossRefPubMed
28.
Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ: Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett 2004, 366: 241–244. 10.1016/j.neulet.2004.05.067CrossRefPubMed
29.
Garry MG, Hargreaves KM: Enhanced release of immunoreactive CGRP and substance P from spinal dorsal horn slices occurs during carrageenan inflammation. Brain Res 1992, 582: 139–142. 10.1016/0006-8993(92)90328-7CrossRefPubMed
30.
Nanayama T, Kuraishi Y, Ohno H, Satoh M: Capsaicin-induced release of calcitonin gene-related peptide from dorsal horn slices is enhanced in adjuvant arthritic rats. Neurosci Res 1989, 6: 569–572. 10.1016/0168-0102(89)90045-XCrossRefPubMed
31.
Samsam M, Covenas R, Ahangari R, Yajeya J, Narvaez JA, Tramu G: Alterations in neurokinin A-, substance P- and calcitonin gene-related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the trigeminal ganglion. Neurosci Lett 1999, 261: 179–182. 10.1016/S0304-3940(98)00989-6CrossRefPubMed
32.
Morton CR, Hutchison WD: Release of sensory neuropeptides in the spinal cord: studies with calcitonin gene-related peptide and galanin. Neuroscience 1989, 31: 807–815. 10.1016/0306-4522(89)90443-0CrossRefPubMed
33.
Schaible HG, Ebersberger A, Peppel P, Beck U, Messlinger K: Release of immunoreactive substance P in the trigeminal brain stem nuclear complex evoked by chemical stimulation of the nasal mucosa and the dura mater encephali–a study with antibody microprobes. Neuroscience 1997, 76: 273–284.CrossRefPubMed
34.
Morton CR, Hutchison WD: Morphine does not reduce the intraspinal release of calcitonin gene-related peptide in the cat. Neurosci Lett 1990, 117: 319–324. 10.1016/0304-3940(90)90684-2CrossRefPubMed
35.
Eftekhari S, Edvinsson L: Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci 2011, 12: 112. 10.1186/1471-2202-12-112PubMedCentralCrossRefPubMed
36.
Pauwels PJ, Tardif S, Palmier C, Wurch T, Colpaert FC: How efficacious are 5-HT1B/D receptor ligands: an answer from GTP gamma S binding studies with stably transfected C6-glial cell lines. Neuropharmacology 1997, 36: 499–512. 10.1016/S0028-3908(96)00170-0CrossRefPubMed
37.
Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L: 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 2001, 909: 112–120. 10.1016/S0006-8993(01)02645-2CrossRefPubMed
38.
Ma QP, Hill R, Sirinathsinghji D: Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur J Neurosci 2001, 13: 2099–2104. 10.1046/j.0953-816x.2001.01586.xCrossRefPubMed
39.
40.
Rocha NF, Rios ER, Carvalho AM, Freire LV, Dias ML, de Franca Fonteles MM, de Sousa FC: Synergistic effect of the L-tryptophan and kynurenic acid with dipyrone or paracetamol in mice. Chem Biol Interact 2013, 205: 148–156. 10.1016/j.cbi.2013.07.005CrossRefPubMed
41.
Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R: Identification and quantification of kynurenic acid in human brain tissue. Brain Res 1988, 454: 164–169. 10.1016/0006-8993(88)90815-3CrossRefPubMed
42.
43.
Wolf H: The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl 1974, 136: 1–186.PubMed
44.
Birch PJ, Grossman CJ, Hayes AG: Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 1988, 151: 313–315. 10.1016/0014-2999(88)90814-XCrossRefPubMed
45.
Knyihar-Csillik E, Toldi J, Krisztin-Peva B, Chadaide Z, Nemeth H, Fenyo R, Vecsei L: Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci Lett 2007, 418: 122–126. 10.1016/j.neulet.2007.03.007CrossRefPubMed
46.
Knyihar-Csillik E, Mihaly A, Krisztin-Peva B, Robotka H, Szatmari I, Fulop F, Toldi J, Csillik B, Vecsei L: The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci Res 2008, 61: 429–432. 10.1016/j.neures.2008.04.009CrossRefPubMed
47.
Vamos E, Fejes A, Koch J, Tajti J, Fulop F, Toldi J, Pardutz A, Vecsei L: Kynurenate derivative attenuates the nitroglycerin-induced CamKIIalpha and CGRP expression changes. Headache 2010, 50: 834–843.CrossRefPubMed
48.
Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F: LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004, 24: 596–602. 10.1111/j.1468-2982.2004.00723.xCrossRefPubMed
49.
Tallaksen-Greene SJ, Young AB, Penney JB, Beitz AJ: Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci Lett 1992, 141: 79–83. 10.1016/0304-3940(92)90339-9CrossRefPubMed
50.
Shigemoto R, Ohishi H, Nakanishi S, Mizuno N: Expression of the mRNA for the rat NMDA receptor (NMDAR1) in the sensory and autonomic ganglion neurons. Neurosci Lett 1992, 144: 229–232. 10.1016/0304-3940(92)90756-WCrossRefPubMed
51.
Wang MW, Kumar U, Dong XD, Cairns BE: Expression of NMDA and oestrogen receptors by trigeminal ganglion neurons that innervate the rat temporalis muscle. Chin J Dent Res 2012, 15: 89–97.PubMed
52.
Lee J, Ro JY: Differential regulation of glutamate receptors in trigeminal ganglia following masseter inflammation. Neurosci Lett 2007, 421: 91–95. 10.1016/j.neulet.2007.05.031PubMedCentralCrossRefPubMed
53.
Sahara Y, Noro N, Iida Y, Soma K, Nakamura Y: Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 1997, 17: 6611–6620.PubMed
54.
Kung LH, Gong K, Adedoyin M, Ng J, Bhargava A, Ohara PT, Jasmin L: Evidence for glutamate as a neuroglial transmitter within sensory ganglia. PLoS One 2013, 8: e68312. 10.1371/journal.pone.0068312PubMedCentralCrossRefPubMed
55.
Lee J, Chung MK, Ro JY: Activation of NMDA receptors leads to phosphorylation of TRPV1 S800 by protein kinase C and A-Kinase anchoring protein 150 in rat trigeminal ganglia. Biochem Biophys Res Commun 2012, 424: 358–363. 10.1016/j.bbrc.2012.07.008PubMedCentralCrossRefPubMed
56.
Song JH, Park ES, Han SM, Han SR, Ahn DK, Youn DH: Signal transduction mechanisms underlying group I mGluR-mediated increase in frequency and amplitude of spontaneous EPSCs in the spinal trigeminal subnucleus oralis of the rat. Mol Pain 2009, 5: 50. 10.1186/1744-8069-5-50PubMedCentralCrossRefPubMed
57.
Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21: 7463–7473.PubMed
58.
Liu L, Chang GQ, Jiao YQ, Simon SA: Neuronal nicotinic acetylcholine receptors in rat trigeminal ganglia. Brain Res 1998, 809: 238–245. 10.1016/S0006-8993(98)00862-2CrossRefPubMed
59.
Ohshiro H, Tonai-Kachi H, Ichikawa K: GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem Biophys Res Commun 2008, 365: 344–348. 10.1016/j.bbrc.2007.10.197CrossRefPubMed
60.
Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L: Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006, 281: 22021–22028. 10.1074/jbc.M603503200CrossRefPubMed
61.
Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K: Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 2008, 507: 1277–1299. 10.1002/cne.21607CrossRefPubMed
Metadata
Title
Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate
Authors
Charlotte Kageneck
Barbara E Nixdorf-Bergweiler
Karl Messlinger
Michael JM Fischer
Publication date
01-12-2014
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2014
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-15-7

Other articles of this Issue 1/2014

The Journal of Headache and Pain 1/2014 Go to the issue

Research article

The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder

Erratum

Erratum to: Hemicrania continua- building on experience and clinical science

Research article

Elevated audiovisual temporal interaction in patients with migraine without aura

Research article

Influences of smoking and caffeine consumption on trigeminal pain processing

Letter to the Editor

Hemicrania continua: towards a new classification?

Research article

Fraud in a population-based study of headache: prevention, detection and correction